Form 4 for CRL Charles River Laboratories
Accepted 2022-05-13 00:00:00 ET · period of report 2022-05-11 · accession 0001127602-22-014473 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-05-13 | 2022-05-11 | CRL | MACKAY MARTIN | Dir | A - Grant | $0.00 | +841 | 10.2K | +9% | $0 |
| D | 2022-05-13 | 2022-05-11 | CRL | MACKAY MARTIN | Dir | A - Grant | $222.31 | +1,512 | 1,512 | New | +$336.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-11 | A | A | 292 | $0.00 | 10,503 | D | — | — | (F2) The grant was made in lieu of director service fees for the term commencing May 10, 2022. The restricted stock units vest upon the earlier of 5/11/2023, or the business day prior to the Company's next annual meeting of shareholders. |
| 2 | Common | Common Stock | 2022-05-11 | A | A | 549 | $0.00 | 10,211 | D | — | — | (F1) The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. |
| 3 | Derivative | Stock Options (Right to Buy) | 2022-05-11 | A | A | 1,512 | $222.31 | 1,512 | D | $222.31 · 2023-05-11 to 2032-05-11 | 1,512 Common Stock | (F3) The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. |